Last reviewed · How we verify
PMX-30063-investigational drug
PMX-30063-investigational drug is a Small molecule drug developed by PolyMedix, Inc.. It is currently in Phase 2 development.
At a glance
| Generic name | PMX-30063-investigational drug |
|---|---|
| Sponsor | PolyMedix, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Initial Treatment for Acute Bacterial Skin Infections (ABSSSI) Caused by Staphylococcus Aureus (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PMX-30063-investigational drug CI brief — competitive landscape report
- PMX-30063-investigational drug updates RSS · CI watch RSS
- PolyMedix, Inc. portfolio CI
Frequently asked questions about PMX-30063-investigational drug
What is PMX-30063-investigational drug?
PMX-30063-investigational drug is a Small molecule drug developed by PolyMedix, Inc..
Who makes PMX-30063-investigational drug?
PMX-30063-investigational drug is developed by PolyMedix, Inc. (see full PolyMedix, Inc. pipeline at /company/polymedix-inc).
What development phase is PMX-30063-investigational drug in?
PMX-30063-investigational drug is in Phase 2.
Related
- Manufacturer: PolyMedix, Inc. — full pipeline
- Compare: PMX-30063-investigational drug vs similar drugs
- Pricing: PMX-30063-investigational drug cost, discount & access